ArticleCellular and molecular life sciences : CMLS2025
CMTM7 inhibits TLR4 signaling pathway via promoting Rab5 activation and alleviates acute liver injury.
Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- GHSR and TLR4 collectively promote hepatic inflammation and aberrant repair in alveolar echinococcosis.Frontiers in immunology · 2026Article
- Effects of Echinacea Purpurea Polysaccharides on Growth Performance, Serum Biochemistry, and Intestinal Health of Immunosuppressed Broilers.Animals : an open access journal from MDPI · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The activation of macrophages mediated by TLR4 is crucial for innate immune responses, while the regulatory mechanisms of TLR4 are still under investigation. This study demonstrates that CMTM7 inhibits TLR4 pathway activation in macrophages and exerts a protective role in acute liver injury (ALI). CMTM7 is highly expressed in monocytes/macrophages, which is downregulated upon LPS stimulation. CMTM7 inhibits LPS/HMGB1-induced activation of the TLR4 pathway in macrophages. Mechanistically, CMTM7 promotes the binding between Rab5 and Gapex5, leading to the generation of GTP-Rab5, which facilitates the internalization and degradation of TLR4, thereby inhibiting TLR4 signaling activation. Utilizing Cmtm7 myeloid conditional knockout mice, we confirmed the protective role of CMTM7 in ALI and highlighted its therapeutic potential through the adoptive transfer of CMTM7-overexpressing macrophages. This study elucidates a novel regulatory mechanism of TLR4 signaling transduction and provides a novel therapeutic strategy for ALI treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.